| pubmed-article:8666572 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8666572 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8666572 | lifeskim:mentions | umls-concept:C0028768 | lld:lifeskim |
| pubmed-article:8666572 | lifeskim:mentions | umls-concept:C0073393 | lld:lifeskim |
| pubmed-article:8666572 | lifeskim:mentions | umls-concept:C1293122 | lld:lifeskim |
| pubmed-article:8666572 | lifeskim:mentions | umls-concept:C1420401 | lld:lifeskim |
| pubmed-article:8666572 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:8666572 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:8666572 | pubmed:dateCreated | 1996-8-8 | lld:pubmed |
| pubmed-article:8666572 | pubmed:abstractText | Although serotonin reuptake inhibitors (SRIs) are the mainstay of pharmacologic treatment for obsessive-compulsive disorder (OCD), many patients do not have an adequate response to these medications. One approach to treating SRI-refractory OCD patients has been to add other classes of medications to the SRI. We predicted that augmentation with risperidone would alleviate symptoms in SRI-refractory OCD patients. | lld:pubmed |
| pubmed-article:8666572 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8666572 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8666572 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8666572 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8666572 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8666572 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8666572 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8666572 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:8666572 | pubmed:issn | 0160-6689 | lld:pubmed |
| pubmed-article:8666572 | pubmed:author | pubmed-author:WangDD | lld:pubmed |
| pubmed-article:8666572 | pubmed:author | pubmed-author:SaxenaSS | lld:pubmed |
| pubmed-article:8666572 | pubmed:author | pubmed-author:BystritskyAA | lld:pubmed |
| pubmed-article:8666572 | pubmed:author | pubmed-author:BaxterL RLRJr | lld:pubmed |
| pubmed-article:8666572 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8666572 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:8666572 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8666572 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8666572 | pubmed:pagination | 303-6 | lld:pubmed |
| pubmed-article:8666572 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:meshHeading | pubmed-meshheading:8666572-... | lld:pubmed |
| pubmed-article:8666572 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8666572 | pubmed:articleTitle | Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. | lld:pubmed |
| pubmed-article:8666572 | pubmed:affiliation | Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA. | lld:pubmed |
| pubmed-article:8666572 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8666572 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8666572 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8666572 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8666572 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8666572 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8666572 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8666572 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8666572 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8666572 | lld:pubmed |
